180 Life Sciences Corp.
ATNF
$0.8599
-$0.0011-0.13%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.36M | 4.85M | 6.70M | 8.24M | 10.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.32M | 6.37M | 8.93M | 10.77M | 13.48M |
| Operating Income | -6.32M | -6.37M | -8.93M | -10.77M | -13.48M |
| Income Before Tax | -6.46M | -3.13M | -14.90M | -18.59M | -22.28M |
| Income Tax Expenses | -296.00K | -4.40K | -2.35M | -2.35M | -2.35M |
| Earnings from Continuing Operations | -6.17 | -3.12 | -12.55 | -16.24 | -19.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.17M | -3.12M | -12.55M | -16.24M | -19.94M |
| EBIT | -6.32M | -6.37M | -8.93M | -10.77M | -13.48M |
| EBITDA | -6.25M | -6.29M | -8.83M | -10.66M | -13.37M |
| EPS Basic | -13.47 | -4.49 | -28.16 | -41.54 | -64.01 |
| Normalized Basic EPS | -3.40 | -3.14 | -7.89 | -16.14 | -30.18 |
| EPS Diluted | -13.47 | -4.50 | -28.17 | -41.55 | -64.02 |
| Normalized Diluted EPS | -3.40 | -3.14 | -7.89 | -16.14 | -30.18 |
| Average Basic Shares Outstanding | 3.66M | 3.16M | 2.60M | 1.96M | 1.51M |
| Average Diluted Shares Outstanding | 3.66M | 3.16M | 2.60M | 1.96M | 1.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |